The Journal of Urology
Volume 179, Issue 2 , Pages 616-621 , February 2008

The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study

  • Claus G. Roehrborn

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Moss Clinical Science Building (J) 8 142, Dallas, Texas 75390-9110 (telephone: 001-214-648-2941; FAX: 001-214-648-0365).
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Paul Siami

      Affiliations

    • Welborn Clinic, Evansville, Indiana
    • Financial interest and/or other relationship with Pfizer, GlaxoSmithKline, Astellas, Merck and Indevus.
    • ,
  • Jack Barkin

      Affiliations

    • Department of Urology, University of Toronto, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Ronaldo Damião

      Affiliations

    • Serviço de Urologia, Hospital Universitário Pedro Ernesto-Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Kim Major-Walker

      Affiliations

    • Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Betsy Morrill

      Affiliations

    • Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Francesco Montorsi

      Affiliations

    • Department of Urology, Universita Vita Salute San Raffaele, Milan, Italy
    • Financial interest and/or other relationship with Pfizer, Eli Lilly, Bayer, Pierre Fabre and GlaxoSmithKline.
    • ,
  • CombAT Study Group

Received 30 June 2007

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 For another article on a related topic see page 770.

 Supported by GlaxoSmithKline.

PII: S0022-5347(07)02586-4

doi: 10.1016/j.juro.2007.09.084

The Journal of Urology
Volume 179, Issue 2 , Pages 616-621 , February 2008

Article Tools

* Image Usage & Resolution